Choose Your News
Loading...
Thumbnail
oligonucleotide therapeutics. A recent publication shows that the thirty year path from the initiation of research on oligonucleotides as therapeutics to the emergence of effective... [Read More]
Thumbnail
ABC7 News and Weather online for Southwest Florida, serving Lee, Collier, Charlotte, Desoto, Glades and Hendry counties... [Read More]
Thumbnail
Biogen's SPINRAZA® Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living wit... [Read More]
Thumbnail
Spinal muscular atrophy, or SMA, is the number one genetic cause of death for infants today. Spinraza, or nusinersen, was approved by the FDA in... [Read More]
ABC FOX Montana provides local news, breaking news, weather, sports and information for Western and South Central Montana. Tune in to the ABC News at... [Read More]
‍new data reaffirm clinically meaningful benefit of Spinraza (nusinersen) in individuals with spinal muscular atrophy across disease severity​... [Read More]
Thumbnail
Biogen (NASDAQ: BIIB) will present robust efficacy and safety data from Phase 2 and 3 SPINRAZA® (nusinersen) studies at the Cure SMA 2017 Annual S... [Read More]
On June 10, students from Professor Craig Merlic's Honors Seminar for Chemistry 89 held a poster session focused on new medicines. At the event held in... [Read More]
Babies with a fatal muscle-wasting condition are being denied access to the only drug that could help them because of NHS capacity problems.Type 1 spinal... [Read More]
Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients... [Read More]
ABC7 News and Weather online for Southwest Florida, serving Lee, Collier, Charlotte, Desoto, Glades and Hendry counties... [Read More]
* Spinraza (nusinersen) approved in the European Union as first treatment for spinal muscular atrophy... [Read More]
Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA). [Read More]
Biogen (BIIB) presented new data from the Phase 3 ENDEAR study of SPINRAZA (nusinersen), which demonstrated a statistically significan... [Read More]
ABC7 News and Weather online for Southwest Florida, serving Lee, Collier, Charlotte, Desoto, Glades and Hendry counties... [Read More]
Following the FDA's December approval of Spinraza, Biogen Inc (NASDAQ: BIIB)'s commercial form of nusinersen for the treatment of spinal muscular atrophy, ... [Read More]
Biogen Inc (NASDAQ: BIIB) said its newly approved Spinraza (nusinersen) would be available in just one week time. Spinraza is approved to treat spinal ... [Read More]
Biogen and Ionis Pharmaceuticals' Spinraza, or nusinersen, became the first drug to be approved by the FDA as a treatment for pediatric and adult patients... [Read More]
Dr. Richard Finkel of Nemours and colleagues have been studying SMA drug Spinraza (nusinersen) for Ionis Pharmaceuticals and Biogen, which was approved by FDA on... [Read More]
Loading...
Preview